Advertisement


William G. Wierda, MD, PhD, on Lisocabtagene Maraleucel in Relapsed/Refractory CLL: TRANSCEND CLL 004

2025 ASCO Annual Meeting

Advertisement

William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses two abstracts on lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). In Abstract 7037, liso-cel with ibrutinib demonstrated better efficacy and safety compared with liso-cel monotherapy, with statistically significant differences for complete response rate and overall response rate. In Abstract 7039, patients with R/R CLL/SLL who had received two or more prior lines of therapy had improved response, delayed progression, and prolonged survival with liso-cel compared with a real-world cohort treated with standard-of-care therapy. 

 



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Confirmed — I have only corrected spelling errors and left all wording unchanged. Here is the revised transcript as one continuous paragraph: I'd like to summarize 2 posters that I'm presenting at ASCO this year. Poster 7039 and 7037—7039 is a poster that presents an updated analysis of liso-cel monotherapy and its analysis of a comparison of a standard of care cohort of patients that was collected through multiple databases. Those were all previously treated patients and the concept is to compare outcomes for liso-cel and patients with similar characteristics as those treated on the TRANSCEND 004 trial who received standard of care treatment and their outcomes versus the outcomes for patients treated with liso-cel monotherapy on the TRANSCEND CLL 004 trial. That analysis showed improved outcomes for patients who were treated with liso-cel. These were all previously treated patients, all had had prior exposure to a BTK inhibitor and the BCL2 inhibitor-based therapy. And the progression-free survival was significantly better at a median of 14 months with liso-cel compared to about four months with a standard of care option. And the overall survival was improved with a median overall survival for liso-cel of 33 months and the median overall survival for standard of care of about 14 months. And so this analysis and comparison in the absence of a randomized trial gives us some insight into the improved outcome seen with liso-cel monotherapy compared to a standard of care option. The other abstract is 7037. This was an analysis with a propensity score comparing outcomes for patients treated with liso-cel monotherapy, the CD19 CAR T-cell therapy, versus liso-cel with ibrutinib. Now there is data, historic data, that demonstrated an improved product could be generated if the T cells were harvested for production while patients were on ibrutinib. In addition, for patients treated with liso-cel or with a CD19 CAR T-cell therapy while on ibrutinib, there was an indication of improved progression-free survival and overall outcomes and a reduction potentially of side effects and toxicities. So this analysis was a comparison because the TRANSCEND CLL 004 trial has two cohorts—actually it had three cohorts—but two major cohorts, liso-cel monotherapy and liso-cel plus ibrutinib. And this was an analysis. And overall, the conclusion was that there were improved responses, both complete response rate and overall response rate, for patients who received the combination of liso-cel plus ibrutinib versus patients who received liso-cel monotherapy. Progression-free survival, duration of response, overall survival were similar; side effect and toxicity profile were similar. But clearly there was, based on this propensity score analysis, an improved response rate associated with combination therapy versus liso-cel monotherapy.

Related Videos

Lung Cancer

Martin Reck, MD, PhD, on Postsurgical MRD, Genomic Mutations, and Outcomes in Resectable NSCLC: AEGEAN Trial

Martin Reck, MD, PhD, of LungenClinic Grosshansdorf, Germany, discusses data from the phase III AEGEAN trial that studied perioperative durvalumab and neoadjuvant chemotherapy. Patients who were MRD-positive after surgery had significantly worse disease-free survival compared to MRD-negative patients. In addition, mutations in KEAP1 and KMT2C were associated with MRD positivity and reduced benefit from the regimen, identifying a small high-risk subgroup with poor prognosis (Abstract 8009). 

Lung Cancer

Bjorn Henning Gronberg, MD, PhD, on SCLC: Adjuvant Immunotherapy After CRT

Bjorn Henning Gronberg, MD, PhD, of Norwegian University of Science and Technology (NTNU) and St. Olavs Hospital, presents phase II findings on the efficacy of atezolizumab after chemoradiotherapy (CRT) in limited-stage small cell lung cancer (SCLC) (LBA8005).  

Leukemia

Constantine Si Lun Tam, MD, FRACP, FRCPA, MBBS, on CLL/SLL: First-Line Zanubrutinib Monotherapy in Patients With del(17p)

Constantine Si Lun Tam, MD, FRACP, FRCPA, MBBS, of Alfred Hospital and Monash University, reviews results from the 5-year follow-up of arm C of the SEQUOIA trial of treatment-naive patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (Abstract 7011). 

Pancreatic Cancer

Asaf Maoz, MD, on Pancreatic Surveillance Eligibility Criteria

Asaf Maoz, MD, of Dana-Farber Cancer Institute/Mass General Brigham/Harvard Medical School, discusses the sensitivity of age and family history criteria for determining eligibility for pancreatic cancer surveillance among individuals with a hereditary risk for the malignancy (Abstract 10500). 

CNS Cancers

Manmeet Singh Ahluwalia, MD, MBA, FASCO, on Liquid Biopsy in Glioblastoma

Manmeet Singh Ahluwalia, MD, MBA, FASCO, of Miami Cancer Institute, Baptist Health South Florida, discusses the ongoing LIBERATE trial, which is evaluating safety and technical efficacy of transcranial MR-guided microbubble-enhanced transcranial focused ultrasound for increasing blood circulating tumor and cell-free DNA levels in adults with glioblastoma (Abstract TPS2094). 

Advertisement

Advertisement




Advertisement